Navigation Links
CardioInsight Announces Closing of $7.5 Million Equity Financing
Date:3/14/2012

CLEVELAND, March 14, 2012 /PRNewswire-USNewswire/ -- CardioInsight Technologies Inc., the leading developer of non-invasive electrocardiographic mapping technology, announced today the closing of a $7.5 million Series "C" financing.  The proceeds from the financing will help CardioInsight accelerate clinical and commercial efforts related to its ECVUEadvanced 3D cardiac mapping system. 

(Logo: http://photos.prnewswire.com/prnh/20110531/DC10432LOGO)

CardioInsight recently announced its CE Mark certification and the successful installation of the ECVUE System at its first clinical customer sites.  In the coming months, the Company will focus on securing its FDA regulatory clearance, demonstrating the value of the ECVUE System to improve the mapping of arrhythmias in routine clinical use, and proving its value in Cardiac Resynchronization Therapy (CRT).

"Securing this additional investment provides CardioInsight the ability to accelerate its clinical development and further demonstrate the commercial value of the ECVUE System," said Steve Arless, CEO of CardioInsight.  "Over the next twelve to eighteen months, we will present a growing body of evidence demonstrating the strong clinical utility of our system; ultimately laying the foundation for commercial expansion in Europe, and commercial introduction in the U.S."

CardioInsight has successfully completed commercial installations at three leading centers in Europe, including St. Mary's Hospital in London, England, the Kerckhoff Clinic in Bad Nauheim, Germany, and the Hopital Cardiologique du Haut-Leveque in Bordeaux, France.  This increased clinical use will highlight the ECVUE System's ability to simplify cardiac mapping procedures, reduce procedure time, and expand the use of mapping to new applications, including cardiac resynchronization for heart failure.

About CardioInsight Technologies Inc.

CardioInsight is commercializing a revolutionary technology that non-invasively generates 3D images of the electrical activity of the heart. 
The images help physicians more accurately treat certain heart ailments such as arrhythmias 
and congestive heart failure. The Company's ECVUE system non-invasively generates real-time, whole heart images of 
the electrical activity on the surface of the heart by combining body surface electrical data with
 3D anatomical data obtained from imaging scans. It then reconstructs and
 displays 3D images and other useful measures of cardiac electrical activity as if the
 measurements were taken directly from the surface of the heart. To date, CardioInsight has completed more than 400 patient studies at leading clinical centers in the United States and Europe, including the Cleveland Clinic Foundation, University Hospitals of Cleveland, Loyola University Medical Center, the University of Pennsylvania Medical Center, and the Hopital Cardiologique du Haut-Leveque in Bordeaux, France.  These studies address a broad variety of cardiac arrhythmias, as well as cardiac resynchronization therapy for congestive heart failure, demonstrating the unique clinical value of the ECVUE System.  Results of the studies have been published in leading peer-reviewed journals, and presented at international clinical conferences.  The Company has received its CE Mark and markets the ECVUE System in Europe.

For more information, visit CardioInsight's website at www.cardioinsight.com, or contact us at 216-453-5950.

 


'/>"/>
SOURCE CardioInsight Technologies Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CardioInsight Announces Addition of Jim Hassett to Senior Management Team
2. CardioInsight Announces CE Mark Clearance and European Launch of the ECVUE™ Non-Invasive Electrocardiographic Mapping System
3. Generex Subsidiary Antigen Express Announces Publication of Review Showcasing its Proprietary Therapeutic Vaccine Technology in the Journal Vaccine
4. Heborium Group Announces 23% Increase in 1st Quarter 2012 Revenue
5. S1 Pharmaceuticals Announces New Executive Management and Scientific Advisory Board Appointments
6. Sosei Announces Initiation of Phase I Study for SO-1105
7. Prime Therapeutics Announces CareCentered Contract™ with EMD Serono, Inc. for MS Drug Rebif®
8. ThermoGenesis Announces Webcast of Presentation at Roth Capital Conference
9. Patented Protection Against Counterfeit Pharmaceuticals and Retail Fraud. ICAP Patent Brokerage Announces for Auction a Patented System for Verification of Purchase and Product Legality
10. CVS Caremark Corporation Announces Quarterly Dividend
11. SIRO Clinpharm Announces Appointment of Gopakumar Menon as Chief Executive Officer to Lead the Global Clinical Research Organization
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... PHILADELPHIA , Jan. 18, 2017 The Philadelphia ... three companies developing medical devices for children. The Consortium ... to receive seed grants of $50,000 each. The ... amplifies weak nerve signals, a hand-operated rapid blood delivery system ... ears in babies. ...
(Date:1/18/2017)... , Jan. 18, 2017   Regenicin, Inc. ... biotechnology company specializing in the development and commercialization of ... tissues and organs, recently reported the Company,s operating results ... 2017. As the Company described in its ... a year of substantial accomplishments. The Company,s contract laboratory ...
(Date:1/18/2017)... 2017  Dermata Therapeutics, LLC, a biotechnology company ... variety of dermatological diseases, announces dosing the first ... Phase 2 acne rosacea study. DMT210 is a ... cytokines in the skin responsible for the inflammation ... This clinical trial, DMT210-003, is a 12-week, ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... 19, 2017 , ... Attorney Robert “RC” Pate , founder of The ... the Triumph Over Kid Cancer foundation. Each year, 175,000 children are diagnosed with pediatric ... firsthand the effect of the critical funding gap for research into pediatric cancer research. ...
(Date:1/19/2017)... ... ... Connecticut Dermatology Group (CDG) is proud and excited to welcome back to the ... brings an extensive background in cutting-edge dermatology care and research to Connecticut’s largest ... Kim to the CDG team” said President and Managing Partner Dr. Steven A. Kolenik ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... ... hosts the Atlanta Breast Surgery Symposium, a conference where hundreds of surgeons from ... in breast surgery. Covering topics from cosmetic breast augmentation to breast ...
(Date:1/18/2017)... ... ... From a health perspective, 2017 will clearly be the Year of the Gut. ... health and general physical well-being. The New York Times suggested a “ Gut Makeover ... Charlottesville restaurant, good gut health is clearly on the menu. Threepenny Cafe ...
(Date:1/18/2017)... ... January 18, 2017 , ... The V Foundation for ... V, its official endurance training and fundraising team, to compete in the Boston Marathon ... those inspired to finish the world’s oldest annual marathon to join Team V and ...
Breaking Medicine News(10 mins):